Evaluate the optimal duration and dose of Acoustic Pulse Thrombolysis ™ (APT) treatment using r-tPA administered via the EKOS ™ system:
• Efficacy -Change in RV/LV ratio on CTA at 48hrs
• Safety -As measured by major bleeding within 72hrs
• Anticoagulation therapy using heparin • Acoustic Pulse Thrombolysis ™ treatment using EKOS ™ -following duration and dosage of randomly assigned study cohort 
Key Results
Acute PE patients treated with EKOS ™ showed the following improvements:
• Significant reduction in RV/LV ratios in all cohorts at 48 hours post initiation of procedure.
• RV/LV ratio reduced by 24% (P<0.0001) for the two-hour cohort using only 4mg of r-tPA per device.
• All cohorts had zero to very low bleeding rates. • RV/LV ratio improved significantly across all four cohorts long-term.
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• Multiple Quality of Life (QOL) metrics showed valuable improvements from 30d following EKOS ™ treatment to 365d post-treatment.
• Very low all-cause mortality and recurrent PE rates of 2% each for all cohorts.
RV/LV ratio continued to reduce after 48h p value <0.0001 @ 365d , vol. 8, no. 11, pp. 2436-2442, 2010 . 3. 
OPTALYSE PE STUDY

ACUTE RESULTS:
The EKOS™ system's very low dose and short-duration regimens, in the OPTALYSE PE trial, prove to be as acutely effective as the regimens in previous EKOS™ studies (ULTIMA & SEATTLE II), pointing to a paradigm-changing approach for PE treatment.
LONG-TERM RESULTS:
The EKOS™ System's very low dose and short duration regimens, in the OPTALYSE PE trial, resulted in rapidly improved measures of right-heart function that were maintained for one year. Additionally, the favorable mortality rates, recurrent PE rates, and quality of life results demonstrate long-term benefits of EKOS™ therapy. This data further proves the PE clinical efficacy and safety of the OPTALYSE PE treatment protocols. BTG is a growing international specialist healthcare company that is developing and commercialising products targeting acute care, cancer and vascular diseases.
The company has diversified revenues from sales of its own marketed products and from royalties on partnered products, and is seeking to acquire new programs and products to develop and market to specialist physicians.
To find out more about the BTG International group companies and our products, visit www.btgplc.com. 
